Article
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.
All News
Article
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
Article
How women can reduce the risk of hip fracture?
Article
Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the International Myositis Assessment and Clinical Studies Group (IMACS) steering committee.
Dr. John Cush
Tweet
#ACR22 - SpA Part2
-Comorbidities in Ankylosing Spondylitis
-Early Diagnosis of AxSpA
-Fertility issues in SpA
-Gender in AxSpa
-Inadequate Dosing of HCQ Leads to Hospitalizations in SLE
-JAK inhibitors in RD
-Opioid use in PsA and SpA
https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4
Dr. John Cush
Tweet
#ACR22- SpA Part1
-AI Future of Sacroiliitis Assessment AI in Detecting Sacroiliitis
-AxSpA: gender differences
-Can we alter neonatal gut microbiome to prevent SpA?
-Comorbidities in AxSpA
-Do Disease Activity Measures Really Capture AS in Women?
https://t.co/sFIZz7pKSF https://t.co/CAh5TZ4FEX
Dr. John Cush
Tweet
PreRA to Treat or Not!
Dr. Janet Pope ( @Janetbirdope ) weighs in. #ACR22
https://t.co/778jWLizeW https://t.co/ZHIQTuYyyg
Dr. John Cush
Tweet
Prescribing Methotrexate in Post-Roe Era
Dr. Cassy Sims ( @DrCassySims) reports live from #ACR22.
L09: Impact on Access to Methotrexate in the Post-Roe Era
https://t.co/GwgSqBj5EX https://t.co/WzFGnJyIf3
Dr. John Cush
Tweet
Is exercise the missing medicine in lupus?
Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical Inactivity is Associated with Increased Expression of T cell inflammatory genes in Systemic Lupus.”
https://t.co/LomZ8U8pzj https://t.co/PEZHypeasB
Dr. John Cush
Tweet
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at #ACR22 Convergence.
https://t.co/nrsH7yB7wu https://t.co/TngS4Kk6YK
Dr. John Cush
Tweet
Artificial Intelligence in Detecting Sacroiliitis
Dr. Akhil Sood ( @AkhilSoodMD) discusses Abstract 0383 at #ACR22.
https://t.co/U52eAFOePr https://t.co/8WcecoF5Sr
Dr. John Cush
Tweet
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/HrC1GLZQRR https://t.co/yiHsxhpiWe
Dr. John Cush
Tweet
TIME Mag - "Why Masks Still Matter". 1) COVID is still out there; 2) Influenza on the rise. Authors write "With limited yet mixed data, we would be wise to ...err on the side of masking in high risk, indoor crowded public settings..." https://t.co/l8jiTwAdZz https://t.co/0QUKJDOhjs
Dr. John Cush
Tweet
1st quarter of 2022, only 29% of Medicaid and Medicare users had at least one telehealth visit - down from 46% in all of 2021. (Data from Centers for Medicare & Medicaid Services) https://t.co/RCYjlJOPS3
Dr. John Cush
Tweet
Will a vegetarian diet and exercise actually help RA disease activity?
At #ACR22, a Dutch program targeting a whole food plant-based diet, physical activity, and stress management has shown benefit in DAS28 RA disease activity measures.
https://t.co/W2axkmbs3y https://t.co/5jktGiEk0T
Dr. John Cush
Tweet
Open label trial compared arthroscopic repair to PT in 100 young pts w/ traumatic, MRI proven meniscal tear without knee OA. Outcomes at 24 months - both groups improvved and were not different between groups https://t.co/rbrUAWuKRa https://t.co/OaNTssAvCG
Dr. John Cush
Tweet
Medication adherence is a problem
I assume that when I prescribe something for patients that they fill the prescription (right away) and take it as planned…or is this a pipe dream?
@Janetbirdope weighs in.
https://t.co/qj3insA6fL https://t.co/yV0xlvdNZu
Dr. John Cush
Tweet
Does Evusheld shield people living with rheumatic diseases?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses three key abstracts from #ACR22 on Evusheld findings.
https://t.co/wYl6Wpd5Fs https://t.co/7T7u4czNOX
Dr. John Cush
Tweet
A look back at #ACR22 Day 1.
https://t.co/UIZnquWAiU https://t.co/EZ2su56J5H
Dr. John Cush
Tweet
FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/6pMwBPFJJr https://t.co/lTdpX0FQwj
